|
1
|
Khaled S, Gantois N, Ly AT, Senghor S, Even G, Dautel E, Dejager R, Sawant M, Baydoun M, Benamrouz-Vanneste S, Chabé M, Ndiaye S, Schacht AM, Certad G, Riveau G, Viscogliosi E. Prevalence and Subtype Distribution of Blastocystis sp. in Senegalese School Children. Microorganisms 2020; 8:microorganisms8091408. [PMID: 32932661 PMCID: PMC7564003 DOI: 10.3390/microorganisms8091408] [Citation(s) in RCA: 53] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Revised: 09/07/2020] [Accepted: 09/10/2020] [Indexed: 12/12/2022] Open
Abstract
Blastocystis sp. is an enteric protozoan that frequently colonizes humans and many animals. Despite impacting on human health, data on the prevalence and subtype (ST) distribution of Blastocystis sp. remain sparse in Africa. Accordingly, we performed the first multicenter and largest epidemiological survey ever conducted on Blastocystis sp. for this continent. A total of 731 stool samples collected from healthy school children living in 10 villages of the northwestern region of Senegal were tested for the presence of Blastocystis sp. by real-time polymerase chain reaction followed by subtyping of positive samples. Considerable variation in prevalence between villages (51.7 to 100%) was evident with the overall prevalence being 80.4%. Mixed infections were identified in 23% of positive individuals. Among 453 school children with a single infection, ST2 was predominant, followed by ST1, ST3, ST7, ST10, and ST14; this is the first report of ST10 and ST14 in humans. Genetic polymorphisms were evident at the intra-ST level with the identification of numerous ST1 to ST3 genotypes. ST1 showed the greatest intra-ST diversity followed by ST2 and ST3. The prevalence and distribution of STs and genotypes varied among target villages, pointing to several potential infection sources, including human-to-human, zoonotic, and waterborne transmission.
Collapse
Affiliation(s)
- Salma Khaled
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
| | - Nausicaa Gantois
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
| | - Amadou Tidjani Ly
- Biomedical Research Center Espoir Pour La Santé (BRC-EPLS), BP 226 Saint-Louis, Senegal; (A.T.L.); (S.S.)
| | - Simon Senghor
- Biomedical Research Center Espoir Pour La Santé (BRC-EPLS), BP 226 Saint-Louis, Senegal; (A.T.L.); (S.S.)
| | - Gaël Even
- Gènes Diffusion, F-59501 Douai, France;
- PEGASE-Biosciences (Plateforme d’Expertises Génomiques Appliquées aux Sciences Expérimentales), Institut Pasteur de Lille, F-59000 Lille, France
| | - Ellena Dautel
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
| | - Romane Dejager
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
| | - Manasi Sawant
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
| | - Martha Baydoun
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
| | - Sadia Benamrouz-Vanneste
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
- Laboratoire Ecologie et Biodiversité, Institut Catholique de Lille, Faculté de Gestion Economie et Sciences, F-59000 Lille, France
| | - Magali Chabé
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
| | - Seynabou Ndiaye
- Région Médicale de Saint-Louis, MSAS, BP 226 Saint-Louis, Senegal;
| | - Anne-Marie Schacht
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
- Biomedical Research Center Espoir Pour La Santé (BRC-EPLS), BP 226 Saint-Louis, Senegal; (A.T.L.); (S.S.)
| | - Gabriela Certad
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
- Délégation à la Recherche Clinique et à l’Innovation, Groupement des Hôpitaux de l’Institut Catholique de Lille, F-59000 Lille, France
| | - Gilles Riveau
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
- Biomedical Research Center Espoir Pour La Santé (BRC-EPLS), BP 226 Saint-Louis, Senegal; (A.T.L.); (S.S.)
| | - Eric Viscogliosi
- Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (S.K.); (N.G.); (E.D.); (R.D.); (M.S.); (M.B.); (S.B.-V.); (M.C.); (A.-M.S.); (G.C.); (G.R.)
- Correspondence:
| |
Collapse
|
|
2
|
Sweeney CJ, Saif MW, Lorusso PM, Ducharme MP, Demnati R, Danna M, Rowinsky E, Mita M, Dejager R, Takimoto C. A phase I study of DX 8951f (exatecan mesylate for injection) in patients with renal dysfunction. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. J. Sweeney
- Indiana University, Indianapolis, IN; University of Alabama at Birmingham, Birmingham, AL; Wayne State University, Detroit, MI; MDS Pharma Services, Montreal, PQ, Canada; Daiichi Pharmaceutical Corp, Montvale, NJ; Cancer Therapy & Research Ctr, San Antonio, TX
| | - M. W. Saif
- Indiana University, Indianapolis, IN; University of Alabama at Birmingham, Birmingham, AL; Wayne State University, Detroit, MI; MDS Pharma Services, Montreal, PQ, Canada; Daiichi Pharmaceutical Corp, Montvale, NJ; Cancer Therapy & Research Ctr, San Antonio, TX
| | - P. M. Lorusso
- Indiana University, Indianapolis, IN; University of Alabama at Birmingham, Birmingham, AL; Wayne State University, Detroit, MI; MDS Pharma Services, Montreal, PQ, Canada; Daiichi Pharmaceutical Corp, Montvale, NJ; Cancer Therapy & Research Ctr, San Antonio, TX
| | - M. P. Ducharme
- Indiana University, Indianapolis, IN; University of Alabama at Birmingham, Birmingham, AL; Wayne State University, Detroit, MI; MDS Pharma Services, Montreal, PQ, Canada; Daiichi Pharmaceutical Corp, Montvale, NJ; Cancer Therapy & Research Ctr, San Antonio, TX
| | - R. Demnati
- Indiana University, Indianapolis, IN; University of Alabama at Birmingham, Birmingham, AL; Wayne State University, Detroit, MI; MDS Pharma Services, Montreal, PQ, Canada; Daiichi Pharmaceutical Corp, Montvale, NJ; Cancer Therapy & Research Ctr, San Antonio, TX
| | - M. Danna
- Indiana University, Indianapolis, IN; University of Alabama at Birmingham, Birmingham, AL; Wayne State University, Detroit, MI; MDS Pharma Services, Montreal, PQ, Canada; Daiichi Pharmaceutical Corp, Montvale, NJ; Cancer Therapy & Research Ctr, San Antonio, TX
| | - E. Rowinsky
- Indiana University, Indianapolis, IN; University of Alabama at Birmingham, Birmingham, AL; Wayne State University, Detroit, MI; MDS Pharma Services, Montreal, PQ, Canada; Daiichi Pharmaceutical Corp, Montvale, NJ; Cancer Therapy & Research Ctr, San Antonio, TX
| | - M. Mita
- Indiana University, Indianapolis, IN; University of Alabama at Birmingham, Birmingham, AL; Wayne State University, Detroit, MI; MDS Pharma Services, Montreal, PQ, Canada; Daiichi Pharmaceutical Corp, Montvale, NJ; Cancer Therapy & Research Ctr, San Antonio, TX
| | - R. Dejager
- Indiana University, Indianapolis, IN; University of Alabama at Birmingham, Birmingham, AL; Wayne State University, Detroit, MI; MDS Pharma Services, Montreal, PQ, Canada; Daiichi Pharmaceutical Corp, Montvale, NJ; Cancer Therapy & Research Ctr, San Antonio, TX
| | - C. Takimoto
- Indiana University, Indianapolis, IN; University of Alabama at Birmingham, Birmingham, AL; Wayne State University, Detroit, MI; MDS Pharma Services, Montreal, PQ, Canada; Daiichi Pharmaceutical Corp, Montvale, NJ; Cancer Therapy & Research Ctr, San Antonio, TX
| |
Collapse
|
|
3
|
Pecking A, Gougeonbertrand F, Lokiec F, Murray J, Subramanian R, Boudinet A, Floiras J, Haspel M, Klein J, Shaban S, Dejager R, Hanna M. Radioimmunolymphoscintigraphy in the preoperative staging of primary breast cancer. Int J Oncol 1996; 9:659-67. [PMID: 21541566 DOI: 10.3892/ijo.9.4.659] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Thirty-one primary breast cancer patients were evaluated by radioimmunolymphoscintigraphy (RILS) and ex vivo scintigraphy (EVS) following subcutaneous injection of human monoclonal antibody In-111-LiLo-16.88. Lymph nodes (370) were assessed by EVS, pathology and immunohistochemistry. The positive predictive value (EVS) for antigen positive nodes, metastatic and hyperplastic, was 90% in stages O-IIB, and the sensitivity and specificity for all stages were 60% and 80% respectively. Four EVS positive nodes with follicular hyperplasia contained micrometastases. RILS and EVS correlate well by the Spearman Rank test (R=0.87). These results suggest RILS may be clinically useful and selectively limit the extent of the surgical procedure.
Collapse
|